R J Fontana
Overview
Explore the profile of R J Fontana including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
934
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rao H, Wu E, Fu S, Yang M, Feng B, Lin A, et al.
Aliment Pharmacol Ther
. 2017 Aug;
46(8):731-740.
PMID: 28833342
Background: Chronic hepatitis C virus (HCV) infection is the leading cause of cirrhosis and hepatocellular carcinoma (HCC) in the United States (US) and an emerging cause in China. Aim: To...
2.
Shaikh S, Tischer S, Choi E, Fontana R
J Clin Pharm Ther
. 2017 May;
42(5):646-648.
PMID: 28543822
What Is Known And Objective: Limited data exist surrounding the metabolism and safety of garlic supplements. Case Description: A patient with a history of hepatopulmonary syndrome (HPS) and orthotopic liver...
3.
Koch D, Speiser J, Durkalski V, Fontana R, Davern T, McGuire B, et al.
Am J Gastroenterol
. 2017 Apr;
112(9):1389-1396.
PMID: 28440304
Objectives: Acute liver failure (ALF) is classically defined by coagulopathy and hepatic encephalopathy (HE); however, acute liver injury (ALI), i.e., severe acute hepatocyte necrosis without HE, has not been carefully...
4.
Editorial: hepatocellular carcinoma--a rare complication of hepatic venous outflow tract obstruction
Parikh N, Fontana R
Aliment Pharmacol Ther
. 2015 May;
41(11):1212-3.
PMID: 25939464
No abstract available.
5.
Foureau D, Walling T, Maddukuri V, Anderson W, Culbreath K, Kleiner D, et al.
Clin Exp Immunol
. 2014 Nov;
180(1):40-51.
PMID: 25418487
Drug-induced liver injury (DILI) is often caused by innate and adaptive host immune responses. Characterization of inflammatory infiltrates in the liver may improve understanding of the underlying pathogenesis of DILI....
6.
Talaat N, Yapali S, Fontana R, Conjeevaram H, Lok A
J Viral Hepat
. 2014 Oct;
22(5):481-8.
PMID: 25311830
With the approval of 2 direct-acting antivirals (DAAs) in 2011 and anticipation of interferon (IFN)-free regimens, more hepatitis C virus (HCV) chronically infected patients are now seeking treatment. To describe...
7.
Singal A, Salameh H, Kuo Y, Fontana R
Aliment Pharmacol Ther
. 2013 May;
38(2):98-106.
PMID: 23713520
Background: Five oral nucleos(t)ide analogues are available to treat chronic hepatitis B (CHB). With the availability of newer agents, their efficacy on incidence of hepatocellular carcinoma (HCC) is not well...
8.
Rangnekar A, Fontana R
J Viral Hepat
. 2013 May;
20(6):377-84.
PMID: 23647954
Studies of IL-28B genotype in patients with hepatitis C virus (HCV) genotype 2/3 infection have yielded conflicting results. The aim of this meta-analysis was to obtain a pooled odds ratio...
9.
Fontana R, Hughes E, Bifano M, Appelman H, Dimitrova D, Hindes R, et al.
Am J Transplant
. 2013 Apr;
13(6):1601-5.
PMID: 23593993
Recurrent HCV infection following liver transplantation can lead to accelerated allograft injury that is difficult to treat with interferon. The aim of this study is to describe the first ever...
10.
Rangnekar A, Fontana R
Aliment Pharmacol Ther
. 2012 May;
36(2):104-14.
PMID: 22612303
Background: Polymorphisms in the IL-28B region are a strong predictor of sustained virologic response (SVR) in individual studies of HCV genotype 1 patients receiving peginterferon (pegIFN) and ribavirin. Aim: To...